Enhancing drug development capabilities and strengthening competitiveness by expanding the generic oncology portfolio and promoting improved new drug development
[by Kang, In Hyo] HLB 바카라사이트 신고's continued R&D investments to strengthen its drug development capabilities are producing tangible outcomes. The company announced on November 28 that it has secured bioequivalence (BE) approval for five generic drugs this year, including the first generic formulation of the oral anticoagulant edoxaban.
The portfolio includes the dyslipidemia combination treatment pitavastatin + ezetimibe, the nonsteroidal anti-inflammatory drug (NSAID) pelubiprofen, the allergic rhinitis treatment pranlukast, and the asthma and allergic rhinitis treatment montelukast. With the combined market size of these five active ingredients estimated at around KRW 500 billion (approximately USD 339.8 million), HLB 바카라사이트 신고 plans to enter the market and expand its share on the basis of the demonstrated bioequivalence.
HLB 바카라사이트 신고 is leveraging the production technologies and quality control expertise it has built through contract manufacturing to broaden its business into 바카라사이트 신고 development and continuously strengthen competitiveness in the generic drug sector. The company is currently seeking approval for a generic version of enzalutamide, a treatment for prostate cancer, which it expects will serve as a springboard for expanding its lineup of generic anticancer drugs and actively targeting the general hospital market.
HLB 바카라사이트 신고 intends to further extend its R&D capabilities, established through its generic drug development efforts, into the creation of its own incrementally modified drugs (IMDs) and further strengthen product competitiveness. The company is also advancing plans to construct the Hyangnam GMP (Good Manufacturing Practice) facility for the production of its generic and IMD products, with completion targeted for 2026. This initiative is expected to bolster profitability and market confidence by simultaneously securing cost competitiveness and robust quality control.
"The investments we have made in pharmaceutical development are now yielding tangible outcomes. We will continue to reinforce our product competitiveness by strengthening our capabilities in generic drug development and pursuing steady growth through the development of generic anticancer drugs and improved novel medicines," said Park Jae-hyung, CEO of HLB Pharmaceutical.